MetaCap

Adicet Bio (ACET) vs CervoMed (CRVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adicet Bio (ACET) has outperformed CervoMed (CRVO) over the past year, losing 77.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -98.6% for ACET. CervoMed is the larger company by market cap ($22.1 million vs $20.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%CRVO-83.56%
+17%-37%-90%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%CRVO-95.01%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus CRVO key metrics
MetricACETCRVO
Share price$2.14$1.46
Market cap$20.03M$22.09M
1-day change-13.01%+9.77%
YTD return-74.58%-81.52%
1-year return-77.78%-83.56%
5-year return-98.58%-95.01%
EPS (TTM)$-7.53$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.01M
Revenue growth (YoY)—-58.86%
Net income (latest FY)$-116.80M$-26.97M
Operating margin—-706.22%
Net margin—-673.06%
52-week high$11.15$10.00
52-week low$2.12$1.27
Distance from 52-week high-80.81%-85.40%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1527.57%+954.79%
Average volume271.05K489.10K
Shares outstanding9.36M15.13M
Employees10215
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ACET vs CRVO FAQ

Which is bigger, Adicet Bio or CervoMed?

CervoMed (CRVO) is larger, with a market capitalization of $22.09M compared with $20.03M for Adicet Bio (ACET).

Which stock has performed better over the past year, ACET or CRVO?

ACET returned -77.78% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and CervoMed in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons